ArticleMicrobiology spectrum2023
Polyclonal Spread of Fosfomycin Resistance among Carbapenemase-Producing Members of the
Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 9 citations in OpenAlex.
- Genomic analysis of antibiotic resistance and virulence factors in the uropathogenMicrobial genomics · 2026Article
- Co-occurrence of plasmid-mediated colistin resistance gene, mcr-1 and blaScientific reports · 2026Article
- One-year multicenter surveillance of Fosfomycin resistance Enterobacterales: the rise of FosA3-producingCurrent research in microbial sciences · 2026Article
- Fosfomycin resistance determinants in Escherichia coli isolates of human and animal origin from Iran.Molecular biology reports · 2025Article
- Fosfomycin-resistantJAC-antimicrobial resistance · 2025Article
- Overcoming the drug resistance barrier: progress in fosfomycin combination therapy against multidrug-resistant pathogens.Frontiers in microbiology · 2025Review
- VIM-1-producing Enterobacter asburiae with mobile colistin resistance genes from wastewaters.BMC genomics · 2024Article
- FosA8-producingEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- FosA3 emerging in clinical carbapenemase-producingFrontiers in cellular and infection microbiology · 2024Article
- Fosfomycin resistance mechanisms inFrontiers in cellular and infection microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fosfomycin (FOS) has been recently reintroduced into clinical practice, but its effectiveness against multidrug-resistant (MDR)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.